Stock Screener App

無料 -

インストール

1.05

4.55% -0.05

An 2 Therapeutics Inc (ANTX)

概要ニュース株価時系列 Financials ディスカッション予測

An 2 Therapeutics Inc (ANTX) 最新ニュース

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 earnings call transcript - MSN

Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView

Sangamo Therapeutics IncOn Feb 2, Prathyusha Duraibabu terminated as principal financial officerSEC filing - marketscreener.com

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - GlobeNewswire

Cullinan Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics

FDA lets Intellia resume MAGNITUDE-2 Phase 3 trial for ATTRv-PN - Stock Titan

Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - Yahoo Finance

Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative

Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Yahoo Finance

GSK enters agreement to acquire RAPT Therapeutics - GSK

Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 - BioSpace

Actuate Therapeutics IncReports Positive Phase 2 Trial Data For ElraglusibSEC Filing - TradingView

Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - Finviz

Sustained Therapeutics Reports Positive Phase 2 Results for Its Long-Acting Non-Opioid Medication for Chronic Pain - Yahoo Finance

Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases - Business Wire

Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire

Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewswire

Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz

Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN

Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Yahoo Finance

Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha

High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Insider Monkey

Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health - GlobeNewswire

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewswire

Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas - PR Newswire

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewswire

Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with - The Manila Times

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - The Manila Times

Kyverna Therapeutics to Report Topline Results from - GlobeNewswire

Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - The Globe and Mail

This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC - GlobeNewswire

Rhythm Pharmaceuticals to Announce Preliminary Data from - GlobeNewswire

Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026 - PR Newswire

Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha

Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC PatientsSlideshow (NASDAQ:TARA) 2025-12-04 - Seeking Alpha

Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView — Track All Markets

Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - MarketScreener

Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology - GlobeNewswire

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times

Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology - Yahoo Finance

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - GlobeNewswire

Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance

RPRX

$44.80

1.24%

ROIV

$26.75

0.19%

INCY

$100.75

1.93%

BNTX

$105.76

3.31%

INSM

$146.17

1.52%

ONC

$346.42

1.38%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く